206 related articles for article (PubMed ID: 38553189)
1. Ethanol extract of Cyathulae Radix inhibits osteoclast differentiation and bone loss.
Shi L; Ren L; Li J; Liu X; Lu J; Jia L; Xie B; Tang S; Liu W; Zhang J
Chin J Nat Med; 2024 Mar; 22(3):212-223. PubMed ID: 38553189
[TBL] [Abstract][Full Text] [Related]
2. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
3. Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss.
Han SY; Kim YK
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946658
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
5. Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway.
Li Y; Zhuang Q; Tao L; Zheng K; Chen S; Yang Y; Feng C; Wang Z; Shi H; Shi J; Fang Y; Xiao L; Geng D; Wang Z
Cell Prolif; 2022 Oct; 55(10):e13291. PubMed ID: 35708050
[TBL] [Abstract][Full Text] [Related]
6. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
[TBL] [Abstract][Full Text] [Related]
7. Melittin inhibits osteoclast formation through the downregulation of the RANKL-RANK signaling pathway and the inhibition of interleukin-1β in murine macrophages.
Choe JY; Kim SK
Int J Mol Med; 2017 Mar; 39(3):539-548. PubMed ID: 28204822
[TBL] [Abstract][Full Text] [Related]
8. Cyperus Rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat.
Kum CJ; Kim EY; Kim JH; Lee B; Min JH; Heo J; Kim JH; Yeom M; Sohn Y; Jung HS
J Ethnopharmacol; 2017 Jun; 205():186-194. PubMed ID: 28315458
[TBL] [Abstract][Full Text] [Related]
9. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
[TBL] [Abstract][Full Text] [Related]
10. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
11. Monotropein Protects against Inflammatory Bone Loss and Suppresses Osteoclast Formation and Bone Resorption by Inhibiting NFATc1 via NF-κB and Akt/GSK-3β Pathway.
Zhang Q; Hu S; He Y; Song Z; Shen Y; Zhao Z; Zhang Q; Qin L; Zhang Q
Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235631
[TBL] [Abstract][Full Text] [Related]
12.
Han SY; Kim JH; Jo EH; Kim YK
Molecules; 2021 Mar; 26(7):. PubMed ID: 33810474
[TBL] [Abstract][Full Text] [Related]
13. Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway.
Qiu Z; Li L; Huang Y; Shi K; Zhang L; Huang C; Liang J; Zeng Q; Wang J; He X; Qin L; Wang X
J Orthop Translat; 2022 Mar; 33():55-69. PubMed ID: 35228997
[TBL] [Abstract][Full Text] [Related]
14. Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways.
Hsiao HB; Lin H; Wu JB; Lin WC
Osteoporos Int; 2013 May; 24(5):1663-76. PubMed ID: 23143538
[TBL] [Abstract][Full Text] [Related]
15. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
[TBL] [Abstract][Full Text] [Related]
16. Tetrandrine Attenuates Cartilage Degeneration, Osteoclast Proliferation, and Macrophage Transformation through Inhibiting P65 Phosphorylation in Ovariectomy-induced Osteoporosis.
Shi F; Ni L; Gao YM
Immunol Invest; 2022 Apr; 51(3):465-479. PubMed ID: 33140671
[TBL] [Abstract][Full Text] [Related]
17. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
18. Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL-induced osteoclastogenesis.
Qian Z; Zhong Z; Ni S; Li D; Zhang F; Zhou Y; Kang Z; Qian J; Yu B
J Cell Mol Med; 2020 Sep; 24(17):10112-10127. PubMed ID: 32790170
[TBL] [Abstract][Full Text] [Related]
19. Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis.
Ye X; Jiang J; Yang J; Yan W; Jiang L; Chen Y
Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1080-1089. PubMed ID: 35929595
[TBL] [Abstract][Full Text] [Related]
20. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
